Zahra Foruzandeh, PhD
Assistant Professor of Molecular Genetics
Genetics in Reproductive Disorders Research Group, ACECR, Tabriz, Iran
My research focuses on the intersection of cancer epigenetics, non-coding RNA biology, and computational oncology, with the goal of translating molecular discoveries into non-invasive tools for early cancer detection and personalized therapy. I am particularly interested in the role of miRNAs, circRNAs, and lncRNAs as prognostic biomarkers, and their integration with machine learning models for clinical prediction.
A central driver of my work is the observation that 90% of cancers are diagnosed at advanced stages, where 5‑year survival drops from 90% to 30%; therefore, I focus on developing circulating ncRNA‑based prognostic kits for pre‑cancer detection and have validated seven ncRNA signatures with AUC > 0.85 (e.g., miR‑96‑5p, miR‑196b‑5p, miR‑151a‑5p, MFAP4/miR‑582‑5p).
My current projects include investigating SNP→mRNA→miRNA/circRNA networks in copper metabolism pathways among occupationally exposed workers, developing Random Forest models to predict IVF success (with preliminary improvements in live birth rates), and whole‑exome sequencing analysis to identify recessive variants in consanguineous cohorts with recurrent miscarriage.
I hold a PhD in Molecular Genetics with a thesis on TET-mediated epigenetic regulation by miRNAs in breast cancer.
I have authored over 25 peer-reviewed publications (50% as first/corresponding author).
Zahra Foruzandeh, PhD
Assistant Professor of Molecular Genetics
Genetics in Reproductive Disorders Research Group, ACECR, Tabriz, Iran
My research focuses on the intersection of cancer epigenetics, non-coding RNA biology, and computational oncology, with the goal of translating molecular discoveries into non-invasive tools for early cancer detection and personalized therapy. I am particularly interested in the role of miRNAs, circRNAs, and lncRNAs as prognostic biomarkers, and their integration with machine learning models for clinical prediction.
A central driver of my work is the observation that 90% of cancers are diagnosed at advanced stages, where 5‑year survival drops from 90% to 30%; therefore, I focus on developing circulating ncRNA‑based prognostic kits for pre‑cancer detection and have validated seven ncRNA signatures with AUC > 0.85 (e.g., miR‑96‑5p, miR‑196b‑5p, miR‑151a‑5p, MFAP4/miR‑582‑5p).
My current projects include investigating SNP→mRNA→miRNA/circRNA networks in copper metabolism pathways among occupationally exposed workers, developing Random Forest models to predict IVF success (with preliminary improvements in live birth rates), and whole‑exome sequencing analysis to identify recessive variants in consanguineous cohorts with recurrent miscarriage.
I hold a PhD in Molecular Genetics with a thesis on TET-mediated epigenetic regulation by miRNAs in breast cancer.
I have authored over 25 peer-reviewed publications (50% as first/corresponding author).